Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Director | May 31, 2017 | June 02, 2017 |
| KINETA, INC./DEYMTX · Entity 77778 | Director · Executive Chair | April 01, 2021 | April 02, 2021 |
| MCKESSON CORPMCK · Entity 2904 | Director | August 17, 2020 | August 19, 2020 |
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | Director | January 02, 2026 | January 06, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP, Comm. Ops. | July 20, 2005 | July 22, 2005 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date May 31, 2017 · Filed June 02, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.62 · Expires 2027-05-31 | Direct | 15,000 |
Reported balance
After 2017-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-31 · Grant · Acquired 15,000 · Balance 15,000 F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 31, 2017 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning June 30, 2017.
KINETA, INC./DE
Report date April 01, 2021 · Filed April 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.64 · Expires 2031-03-31 | Direct | 78,650 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 78,650 · Balance 78,650 F1: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest and become exercisable in 48 equal monthly installments over four years following February 1, 2021.
MCKESSON CORP
Report date August 17, 2020 · Filed August 19, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-08-17 transaction · row 1
1 source rowRow 1 · 2020-08-17 · Sale · Disposed 2,453 · Balance 0 |
REGENERON PHARMACEUTICALS, INC.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,714 |
Reported balance
After 2026-01-02 transaction · row 1
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 155 · Balance 1,714 F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $772.76 · Expires 2036-01-02 | Direct | 1,962 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 1,962 · Balance 1,962 F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.
F2: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.
VERTEX PHARMACEUTICALS INC / MA
Report date July 20, 2005 · Filed July 22, 2005
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2015-07-19 | Direct | 272,328 |
Reported balance
After 2005-07-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2005-07-20 · Grant · Acquired 18,000 · Balance 272,328 F1: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005. |
Filing footnotes · ownership attribution and instrument terms
F1: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 07/20/2005.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cerevel Therapeutics Holdings, Inc.
Report date August 01, 2024 · Filed August 05, 2024
Section 16 reporting ended · disclosed 2024-08-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-08-01 · Disposition to issuer · Disposed 15,638 · Balance 10,290 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Row 2 · 2024-08-01 · Disposition to issuer · Disposed 10,290 · Balance 0 F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-08-01 · Disposition to issuer · Disposed 4,809,418 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-08-01 · Disposition to issuer · Disposed 46,322 · Balance 0 F4: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest.
F2: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.
F4: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2026 Filed Jan 6, 2026 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,962 | $0.00 Strike: $772.76 | $0.00 |
DisclosureSEC source: 0001197018-26-000002 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,962 Underlying: Common Stock · 1,962 shares Expires 2036-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 155 | $0.00 | $0.00 |
DisclosureSEC source: 0001197018-26-000002 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,714 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,958 | $0.00 Strike: $719.37 | $0.00 |
DisclosureSEC source: 0001968202-25-000010 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,958 Underlying: Common Stock · 1,958 shares Expires 2035-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 21:12 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 166 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-25-000010 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,559 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerRestricted Stock Units · Derivative | 46,322 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-090789 · ownership.xml · derivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,322 shares Expires not disclosed F4 · derivative.exercise_price: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F4 · derivative.exercise_date: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F4 · derivative.expiration_date: At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerStock Option (Right to Buy) · Derivative | 4,809,418 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090789 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,809,418 shares Expires not disclosed F3 · derivative.exercise_price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 10,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090789 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F2 · price: These shares are represented by restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was cancelled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. Read SEC document |
| August 01, 2024 Filed Aug 5, 2024 16:20 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Disposition to issuerCommon Stock | 15,638 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-090789 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,290 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 6, 2023, by and among AbbVie Inc. ("Parent"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. ("Merger Sub") and Cerevel Therapeutics Holdings, Inc. ("Issuer"), on August 1, 2024 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the "Merger Consideration"), without interest. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-081490 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,177,417 Underlying: Common Stock · 25,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 25,000 | $41.18 | $1,029,535.00 |
DisclosureSEC source: 0000950170-24-081490 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,928 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.85 to $41.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: This number includes 10,290 unvested Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. These RSUs shall vest upon the earlier of: (i) June 5, 2025, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 25,000 | $3.50 | $87,500.00 |
DisclosureSEC source: 0000950170-24-081490 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · balance_after: This number includes 10,290 unvested Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. These RSUs shall vest upon the earlier of: (i) June 5, 2025, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 16:34 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | GrantCommon Stock | 10,290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-070736 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,928 F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. F1 · price: The shares reported in this transaction represent Restricted Stock Units ("RSUs") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. 100% of the RSUs subject to this grant shall vest upon the earlier of: (i) the one-year anniversary of the Grant Date, or (ii) the 2025 annual meeting of stockholders of the Company. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-069284 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,202,417 Underlying: Common Stock · 50,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 50,000 | $40.61 | $2,030,520.00 |
DisclosureSEC source: 0000950170-24-069284 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,638 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.29 to $40.89. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 16:05 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000950170-24-069284 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. Read SEC document |
| May 10, 2024 Filed May 14, 2024 17:16 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-059788 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,252,417 Underlying: Common Stock · 50,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| May 10, 2024 Filed May 14, 2024 17:16 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 50,000 | $42.10 | $2,105,125.00 |
DisclosureSEC source: 0000950170-24-059788 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,638 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $42.005 to $42.32. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 10, 2024 Filed May 14, 2024 17:16 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000950170-24-059788 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-041073 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,302,417 Underlying: Common Stock · 50,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 50,000 | $42.33 | $2,116,640.00 |
DisclosureSEC source: 0000950170-24-041073 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,638 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $42.20 to $42.40. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000950170-24-041073 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-027156 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,352,417 Underlying: Common Stock · 50,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 50,000 | $41.01 | $2,050,550.00 |
DisclosureSEC source: 0000950170-24-027156 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,638 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $40.81 to $41.18. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000950170-24-027156 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:49 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-025036 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,402,417 Underlying: Common Stock · 50,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:49 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 50,000 | $41.16 | $2,057,890.00 |
DisclosureSEC source: 0000950170-24-025036 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,638 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.00 to $41.28. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 29, 2024 Filed Mar 4, 2024 17:49 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000950170-24-025036 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,638 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 19:14 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 2,506 | $41.54 | $104,109.51 |
DisclosureSEC source: 0000950170-24-012953 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,638 F2 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. The sales reported on this Form 4 represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $41.42 to $41.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 19:14 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionRestricted Stock Units · Derivative | 15,440 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-012953 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,322 Underlying: Common Stock · 15,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. F4 · derivative.expiration_date: The RSUs vest in four equal annual installments on each of February 6, 2024, February 6, 2025, February 6, 2026 and February 6, 2027, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 19:14 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 15,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-012953 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 1,607 | $0.00 Strike: $888.34 | $0.00 |
DisclosureSEC source: 0001968202-24-000029 · edgardoc.xml · derivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,607 Underlying: Common Stock · 1,607 shares Expires 2034-01-02 F2 · derivative.exercise_date: On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:11 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | GrantCommon Stock | 135 | $0.00 | $0.00 |
DisclosureSEC source: 0001968202-24-000029 · edgardoc.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,393 F1 · kind: Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-24-001864 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,452,417 Underlying: Common Stock · 50,000 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 50,000 | $42.24 | $2,111,815.00 |
DisclosureSEC source: 0000950170-24-001864 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $42.15 to $42.42. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 50,000 | $3.50 | $175,000.00 |
DisclosureSEC source: 0000950170-24-001864 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated September 18, 2023 adopted by the Reporting Person. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 22,824 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-064517 · ownership.xml · derivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,502,417 Underlying: Common Stock · 22,824 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 22,824 | $25.13 | $573,455.28 |
DisclosureSEC source: 0000950170-23-064517 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.52. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 16:15 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 22,824 | $3.50 | $79,884.00 |
DisclosureSEC source: 0000950170-23-064517 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,528 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 17:03 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-062217 · ownership.xml · derivative · entry 6 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,525,241 Underlying: Common Stock · 100 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 17:03 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 100 | $25.16 | $2,516.00 |
DisclosureSEC source: 0000950170-23-062217 · ownership.xml · nonDerivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. Read SEC document |
| November 08, 2023 Filed Nov 9, 2023 17:03 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 100 | $3.50 | $350.00 |
DisclosureSEC source: 0000950170-23-062217 · ownership.xml · nonDerivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 17:03 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,076 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-062217 · ownership.xml · derivative · entry 5 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,525,341 Underlying: Common Stock · 27,076 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F3 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 17:03 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 27,076 | $25.02 | $677,555.24 |
DisclosureSEC source: 0000950170-23-062217 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.13. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 17:03 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 27,076 | $3.50 | $94,766.00 |
DisclosureSEC source: 0000950170-23-062217 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,780 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 17:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 61,401 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-059520 · ownership.xml · derivative · entry 6 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,552,417 Underlying: Common Stock · 61,401 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 17:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 61,401 | $25.43 | $1,561,458.13 |
DisclosureSEC source: 0000950170-23-059520 · ownership.xml · nonDerivative · entry 4 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.03 to $25.83. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 03, 2023 Filed Nov 6, 2023 17:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 61,401 | $3.50 | $214,903.50 |
DisclosureSEC source: 0000950170-23-059520 · ownership.xml · nonDerivative · entry 3 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,105 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 17:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionStock Option (Right to Buy) · Derivative | 38,599 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0000950170-23-059520 · ownership.xml · derivative · entry 5 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,613,818 Underlying: Common Stock · 38,599 shares Expires 2028-12-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F4 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 17:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | SaleCommon Stock | 38,599 | $25.19 | $972,239.33 |
DisclosureSEC source: 0000950170-23-059520 · ownership.xml · nonDerivative · entry 2 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,704 F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $25.00 to $25.91. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 02, 2023 Filed Nov 6, 2023 17:12 UTC | Cerevel Therapeutics Holdings, Inc. CERE · Entity 15182 | Exercise / conversionCommon Stock | 38,599 | $3.50 | $135,096.50 |
DisclosureSEC source: 0000950170-23-059520 · ownership.xml · nonDerivative · entry 1 COLES N ANTHONY · CIK 0001197018 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: These transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 9, 2022 adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.